News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
697,067 Results
Type
Article (41522)
Company Profile (447)
Press Release (655098)
Section
Business (208265)
Career Advice (1999)
Deals (35933)
Drug Delivery (89)
Drug Development (83242)
Employer Resources (169)
FDA (16312)
Job Trends (15035)
News (351789)
Policy (32977)
Tag
Academia (2621)
Alliances (50546)
Alzheimer's disease (1217)
Approvals (16223)
Artificial intelligence (105)
Bankruptcy (361)
Best Places to Work (11586)
Biotechnology (332)
Breast cancer (86)
Cancer (747)
Career advice (1667)
Cell therapy (185)
Clinical research (65392)
Collaboration (266)
Compensation (146)
COVID-19 (2574)
Cystic fibrosis (82)
Data (615)
Diabetes (111)
Diagnostics (6101)
Drug pricing (80)
Earnings (85021)
Employer resources (146)
Events (111795)
Executive appointments (224)
FDA (16669)
Funding (245)
Gene therapy (136)
GLP-1 (572)
Government (4396)
Healthcare (18965)
Infectious disease (2630)
Inflammatory bowel disease (104)
Interviews (307)
IPO (16521)
Job creations (3693)
Job search strategy (1427)
Layoffs (432)
Legal (7923)
Lung cancer (140)
Manufacturing (129)
Medical device (13241)
Medtech (13246)
Mergers & acquisitions (19369)
Metabolic disorders (334)
Neuroscience (1439)
NextGen Class of 2024 (6710)
Non-profit (4529)
Northern California (1046)
Obesity (200)
Opinion (196)
Patents (86)
People (57387)
Pharmaceutical (86)
Phase I (20449)
Phase II (28845)
Phase III (21383)
Pipeline (168)
Postmarket research (2589)
Preclinical (8762)
Radiopharmaceuticals (248)
Rare diseases (171)
Real estate (5995)
Regulatory (21784)
Research institute (2401)
Resumes & cover letters (351)
Southern California (976)
Startups (3746)
United States (10700)
Vaccines (529)
Weight loss (158)
Date
Today (174)
Last 7 days (591)
Last 30 days (2735)
Last 365 days (37441)
2024 (29508)
2023 (41013)
2022 (52278)
2021 (56769)
2020 (54924)
2019 (47425)
2018 (35701)
2017 (33036)
2016 (32350)
2015 (38405)
2014 (32191)
2013 (27122)
2012 (29229)
2011 (29872)
2010 (28000)
Location
Africa (732)
Arizona (188)
Asia (38324)
Australia (6366)
California (2460)
Canada (1088)
China (184)
Colorado (100)
Connecticut (107)
Europe (83461)
Florida (342)
Georgia (82)
Illinois (299)
Indiana (168)
Kansas (98)
Maryland (480)
Massachusetts (2020)
Michigan (137)
Minnesota (244)
New Jersey (722)
New York (745)
North Carolina (686)
Northern California (1046)
Ohio (120)
Pennsylvania (687)
South America (1107)
Southern California (976)
Texas (337)
Washington State (300)
697,067 Results for "fate therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Biotech Beach
Fate Therapeutics to Present at 2024 Jefferies Global Healthcare Conference
Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE) today announced that the Company will present at the 2024 Jefferies Global Healthcare Conference on Wednesday, June 5, 2024 at 3:00 PM ET in New York, New York.
May 29, 2024
·
1 min read
Biotech Beach
Fate Therapeutics to Present at 23rd Annual Needham Virtual Healthcare Conference
Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE) today announced that the Company will present at the 23rd Annual Needham Virtual Healthcare Conference on Wednesday, April 10, 2024 at 2:15 PM ET.
April 3, 2024
·
1 min read
Biotech Beach
Fate Therapeutics to Present at Upcoming March 2024 Investor Conferences
Fate Therapeutics, Inc. announced that the Company will participate in the following upcoming investor conferences:
March 1, 2024
·
2 min read
Business
Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2024 Financial Results and Operational Updates
Fate Therapeutics, Inc. will host a conference call and live audio webcast on Thursday, May 9, 2024 at 5:00 PM ET to report its first quarter 2024 financial results.
May 6, 2024
·
1 min read
Business
Fate Therapeutics to Present at 2024 Cantor Global Healthcare Conference
September 12, 2024
·
1 min read
Business
Fate Therapeutics Reports First Quarter 2024 Financial Results and Business Updates
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell -derived cellular immunotherapies to patients with cancer and autoimmune diseases, reported business highlights and financial results for the first quarter ended March 31, 2024.
May 9, 2024
·
17 min read
Biotech Beach
Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting
Fate Therapeutics, Inc. (NASDAQ: FATE) today announced that two presentations will be featured at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting, being held in Baltimore, Maryland on May 7-11, 2024.
April 22, 2024
·
6 min read
Business
Fate Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
Fate Therapeutics, Inc. (NASDAQ: FATE) today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2023.
February 26, 2024
·
15 min read
Business
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - June 04, 2024
Fate Therapeutics, Inc. announced that on June 1, 2024 the Company granted a non-qualified stock option to one newly-hired employee to purchase a total of 65,000 shares of the Company’s common stock at an exercise price per share of $3.68, which was the closing price per share of the Company’s common stock as reported by NASDAQ on May 31, 2024.
June 4, 2024
·
3 min read
Biotech Beach
Fate Therapeutics Announces Presentation of FT522 Preclinical Data for Autoimmune Diseases in Late-breaking Abstract at ASGCT Annual Meeting
Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that a late-breaking abstract featuring preclinical data from its FT522 program for autoimmune diseases will be featured at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting.
May 3, 2024
·
6 min read
1 of 69,707
Next
